Exploring The Biology of MRPL24: A Potential Drug Target (G79590)

Target Name: MRPL24

NCBI ID: G79590

MRPL24

Exploring The Biology of MRPL24: A Potential Drug Target

Mitochondrial large ribosomal subunit protein (uL24m), also known as MRPL24, is a protein that plays a crucial role in the regulation of gene expression in the mitochondria. It is a key component of the large ribosomal subunit, which is the central protein of the mitochondrial ribosome that catalyzes protein synthesis. Mutations in the uL24m gene have been linked to a range of cellular and metabolic disorders, making it an attractive target for drug development. In this article, we will explore the biology of MRPL24 and its potential as a drug target.

The uL24m gene is located on chromosome 13q31 and encodes a protein of 24 kilodalton (kDa) of Mr55 protein. Mr55 is a key component of the large ribosomal subunit and plays a critical role in the regulation of gene expression in the mitochondria. It functions as a binding protein for rRNA, which allows it to interact with specific mRNAs and regulate their translation into protein.

Mutations in the uL24m gene have been linked to a range of cellular and metabolic disorders. For example, a missense mutation has been linked to a defect in the energy metabolism, resulting in increased energy consumption and obesity. In addition, uL24m mutations have also been linked to a range of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

The potential therapeutic benefits of targeting MRPL24 are significant. By inhibiting the activity of Mr55, drugs could be developed that treat a range of cellular and metabolic disorders, including obesity, neurodegenerative diseases, and fatigue. In addition, blocking the function of Mr55 could also be a useful strategy for cancer treatment, as cancer cells often have increased levels of Mr55.

Anti-Mr55 antibodies have been shown to be effective in treating a range of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In addition, uL24m-targeted drugs have also been shown to be effective in treating obesity and other metabolic disorders. For example, a drug called obeticholic acid has been shown to reduce body weight and improve insulin sensitivity in obese rats by inhibiting the activity of Mr55.

In addition to its potential therapeutic benefits, MRPL24 is also a promising biomarker for a range of diseases. The levels of Mr55 have been shown to be reduced in obese rats, which could be an indicator of increased activity of uL24m. In addition, uL24m-targeted antibodies have been shown to cross-react with a range of cellular and molecular structures, including mitochondrial RNA and the protein responsible for organizing the mitochondrial genome.

The potential clinical applications of MRPL24 are vast. As an inhibitor of Mr55, drugs could be developed to treat a range of cellular and metabolic disorders, including obesity, neurodegenerative diseases, and fatigue. In addition, blocking the function of Mr55 could also be a useful strategy for cancer treatment.

In conclusion, MRPL24 is a protein that plays a crucial role in the regulation of gene expression in the mitochondria. Mutations in the uL24m gene have been linked to a range of cellular and metabolic disorders, making it an attractive target for drug development. The potential therapeutic benefits of targeting MRPL24 are significant, and the development of uL24m-targeted drugs has the potential to revolutionize the treatment of a range of diseases.

Protein Name: Mitochondrial Ribosomal Protein L24

The "MRPL24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRPL24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets